OncoSil Medical Ltd (ASX: OSL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

OncoSil Medical Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $16.66 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 3.33 billion
Earnings per share -0.008
Dividend per share N/A
Year To Date Return -35.29%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • OncoSil Medical Ltd (ASX: OSL)
    Latest News

    A man in a wheelchair stretches both arms into the air in success.
    Healthcare Shares

    The OncoSil Medical share price is booming 66%. Here's why

    Here's what's boosting the medical device company's stock today.

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    Why is the OncoSil Medical (ASX:OSL) share price surging 18% today?

    The medical device company has some exciting study results...

    Read more »

    China war ASX shares iron ore price record asx share price rise represented by a rising arrow on green chart
    Healthcare Shares

    Why the OncoSil (ASX:OSL) share price finished the day higher today

    The Oncosil Medical Ltd (ASX: OSL) share price finished in positive territory during late-afternoon trade. We take a closer look…

    Read more »

    jump in asx share price represented by man leaping up from one wooden pillar to the next
    Share Market News

    Here's why the OncoSil Medical (ASX:OSL) share price has jumped 10% today

    The OncoSil Medical Ltd (ASX: OSL) share price jumped 10% after receiving Swiss regulatory approval. We take a closer look.

    Read more »

    OSL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About OncoSil Medical Ltd

    OncoSil Medical Ltd is an Australian based medical device company focused on localized radiation treatments for patients with pancreatic and bile duct cancer. The product includes OncoSil, a silicon and phosphorus (p32) beta emitter radiation therapy for the treatment of pancreatic cancer.

    OSL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 May 2024 $0.01 $0.00 0.00% 12,031,599 $0.01 $0.01 $0.01
    27 May 2024 $0.01 $0.00 0.00% 15,518,358 $0.01 $0.01 $0.01
    24 May 2024 $0.01 $0.00 0.00% 41,360,450 $0.01 $0.01 $0.01
    23 May 2024 $0.01 $0.00 0.00% 1,890,999 $0.01 $0.01 $0.00
    22 May 2024 $0.01 $0.00 0.00% 787,233 $0.01 $0.01 $0.00
    21 May 2024 $0.01 $0.00 0.00% 273,005 $0.00 $0.01 $0.00
    20 May 2024 $0.01 $0.00 0.00% 1,426,510 $0.00 $0.01 $0.00
    17 May 2024 $0.01 $0.00 0.00% 20,454 $0.01 $0.01 $0.01
    16 May 2024 $0.01 $0.00 0.00% 6,376,854 $0.01 $0.01 $0.01
    15 May 2024 $0.01 $0.00 0.00% 5,085,049 $0.01 $0.01 $0.00
    14 May 2024 $0.00 $0.00 0.00% 578,283 $0.00 $0.00 $0.00
    13 May 2024 $0.00 $0.00 0.00% 71,668 $0.00 $0.00 $0.00
    10 May 2024 $0.00 $0.00 0.00% 159,300 $0.00 $0.00 $0.00
    09 May 2024 $0.00 $0.00 0.00% 870,000 $0.00 $0.00 $0.00
    08 May 2024 $0.00 $0.00 0.00% 129,000 $0.00 $0.00 $0.00
    07 May 2024 $0.00 $0.00 0.00% 150,000 $0.00 $0.00 $0.00
    06 May 2024 $0.00 $0.00 0.00% 3,850,198 $0.00 $0.01 $0.00
    03 May 2024 $0.01 $0.00 0.00% 9,733,312 $0.01 $0.01 $0.00
    02 May 2024 $0.00 $0.00 0.00% 6,420,109 $0.01 $0.01 $0.00
    01 May 2024 $0.01 $0.00 0.00% 10,463,721 $0.01 $0.01 $0.01
    30 Apr 2024 $0.01 $0.00 0.00% 1,305,983 $0.01 $0.01 $0.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Dec 2023 Nigel Lange Issued 91,500,000 $366,000
    Issue of securities. 96,811,428 Rights, Non-cash
    19 Dec 2023 Gabriel Liberatore Issued 3,000,000 $21,000
    Issue of options. Non-cash
    19 Dec 2023 Doug Cubbin Issued 5,000,000 $35,000
    Issue of options. Non-cash
    30 Jun 2023 Otto Buttula Sell 5,307,693 $63,678
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Nigel Lange Chief Executive OfficerManaging Director Jan 2021
    Mr Lange brings with him over 30 years of experience in the medical devices industry. Since 2003, Nigel has held various leadership roles with Sirtex Medical, a global leader in brachytherapy treatment for liver cancer. From 2003, Nigel served as Chief Executive Officer of Sirtex's European business, responsible for establishing their brachytherapy device in over 300 centres across Europe and Middle East.
    Dr Gabriel Liberatore Non-Executive Director Jul 2023
    Dr Liberatore is a biopharmaceutical executive with over 25 years experience in senior Business Development, R&D and strategic operational management positions including taking products to market. Until recently, he was the Group Chief Operating Officer at Telix Pharmaceuticals (ASX:TLX) a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Currently, Dr Liberatore is a Strategic Advisor to GlyTherix Ltd, an Australian immuno-oncology company specializing in developing antibody radiopharmaceuticals for solid tumours.
    Mr Doug Cubbin Non-Executive Director Aug 2023
    Mr Cubbin is a biopharmaceutical executive with over 30 years' experience in senior executive, CFO, Director and Chair roles, across varied industries. Mr Cubbin has also served as Chairman of various boards, including Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine.
    Christian Dal Cin Chief Financial OfficerCompany Secretary Jun 2023
    -
    Christian Dal Cin Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mrs Sarah Cameron 118,661,215 6.01%
    Alua Capital Pty Ltd 47,653,847 2.41%
    Bannaby Investments Pty Limited <Bannaby Super Fund A/C> 46,000,000 2.33%
    Peter Kyros Pty Ltd Kyros Sf A/C> 44,656,780 2.26%
    Hsbc Custody Nominees (Australia) Limited 38,076,479 1.93%
    Citicorp Nominees Pty Limited 35,052,240 1.77%
    Myconsulting Pty Ltd 34,000,000 1.72%
    Mr Gregory Joseph Harris 32,999,930 1.67%
    Newfound Investments Pty Ltd <Newfound Superannuation A/C> 32,307,694 1.64%
    Sunset Capital Management Pty Ltd <Sunset Superfund A/C> 29,000,000 1.47%
    Netwealth Investments Limited <Wrap Services A/C> 27,228,094 1.38%
    Tisia Nominees Pty Ltd <Henderson Family A/C> 25,845,965 1.31%
    Jk Nominees Pty Ltd <The Jk A/C> 25,000,000 1.27%
    The Trust Company (Australia) Limited <Mbf A/C> 23,000,000 1.16%
    Cabletime Pty Ltd <Ingodwe A/C> 22,553,848 1.14%
    Rojo Nero Capital Pty Ltd 19,360,127 0.98%
    Rogers Sf Management Pty Ltd <Rogers Super Fund A/C> 19,089,355 0.97%
    Ardroy Securities Pty Ltd <Cameron Investment Unit A/C> 16,114,819 0.82%
    Mr Peter Barrett Capp <Capp Family A/C> 15,000,000 0.76%
    MWCD Pty Ltd <Gww Super Fund A/C> 14,553,100 0.74%

    Profile

    since

    Note